GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cell MedX Corp (OTCPK:CMXC) » Definitions » Degree of Financial Leverage

Cell MedX (Cell MedX) Degree of Financial Leverage : 0.88 (As of Feb. 2024)


View and export this data going back to 2013. Start your Free Trial

What is Cell MedX Degree of Financial Leverage?

Degree of Financial Leverage (DFL) measures the percentage change in EPS for a unit change in Earnings Before Interest and Taxes (EBIT). Cell MedX's Degree of Financial Leverage for the quarter that ended in Feb. 2024 was 0.88. The higher Degree of Financial Leverage, the more volatile earnings will be.

The industry rank for Cell MedX's Degree of Financial Leverage or its related term are showing as below:

CMXC's Degree of Financial Leverage is ranked better than
62.32% of 828 companies
in the Medical Devices & Instruments industry
Industry Median: 0.99 vs CMXC: 0.88

Cell MedX Degree of Financial Leverage Historical Data

The historical data trend for Cell MedX's Degree of Financial Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cell MedX Degree of Financial Leverage Chart

Cell MedX Annual Data
Trend May14 May15 May16 May17 May18 May19 May20 May21 May22 May23
Degree of Financial Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.13 5.76 1.23 37.51 1.00

Cell MedX Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Degree of Financial Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.82 1.00 0.73 0.65 0.88

Competitive Comparison of Cell MedX's Degree of Financial Leverage

For the Medical Devices subindustry, Cell MedX's Degree of Financial Leverage, along with its competitors' market caps and Degree of Financial Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cell MedX's Degree of Financial Leverage Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cell MedX's Degree of Financial Leverage distribution charts can be found below:

* The bar in red indicates where Cell MedX's Degree of Financial Leverage falls into.



Cell MedX Degree of Financial Leverage Calculation

Cell MedX's Degree of Financial Leverage for the quarter that ended in Feb. 2024 is calculated as:

Degree of Financial Leverage=% Change in Earnings per Share (Diluted)**/% Change in EBIT
=( -0.001 (Feb. 2024) / -0.006 (Feb. 2023) - 1 )/( -0.029 (Feb. 2024) / -0.537 (Feb. 2023) - 1 )
=-0.8333/-0.946
=0.88***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EPS and EBIT was used to calculate Degree of Financial Leverage.
*** Please be aware that the Degree of Financial Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Cell MedX  (OTCPK:CMXC) Degree of Financial Leverage Explanation

Degree of Financial Leverage (DFL) is a leverage ratio that measures the sensitivity of a company’s Earnings per Share (EPS) to fluctuations in its operating income, also referred to as Earnings Before Interest and Taxes (EBIT), resulting from adjustments in its capital structure. DFL is an essential tool for companies to assess the appropriate level of debt or financial leverage in their capital structure. When EBIT remains relatively stable, it results in stable earnings and earnings per share. In such cases, the company may consider taking on substantial debt. However, for companies operating in industries with significant fluctuations in EBIT, it is advisable to keep debt at a manageable level.

The higher Degree of Financial Leverage, the more volatile earnings will be. Because interest is a fixed expense, leverage can amplify earnings and EPS. This is beneficial when EBIT is growing, but it can become problematic in tough economic conditions when EBIT is under pressure.

Be Aware

The use of financial leverage varies across different industries and business sectors, and the application of Degree of Financial Leverage (DFL) should be adjusted accordingly.


Cell MedX Degree of Financial Leverage Related Terms

Thank you for viewing the detailed overview of Cell MedX's Degree of Financial Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Cell MedX (Cell MedX) Business Description

Traded in Other Exchanges
N/A
Address
123 W. Nye Lane, Suite 446, Carson City, NV, USA, 89706
Cell MedX Corp is an early stage development company focused on the discovery, development and, commercialization of therapeutic products for patients with diseases such as diabetes, by developing technologies to help manage the illness and related complications. The company's product portfolio consists of electromedical technologies, ebalance, and others.
Executives
Richard Jeffs 10 percent owner FLAT 7, 6 ENNISMORE GARDENS, LONDON X0 SW7 1NL
Dwayne Yaretz director, officer: Chief Executive Officer SUITE 1050 WEST PENDER STREET SUITE 2250, VANCOUVER A1 V6E 3S7
Bradley S Hargreaves 10 percent owner 904-1616 BAYSHORE DR, VANCOUVER A1 V6G3L1
Frank Mcenulty director, officer: CEO, CFO, Treas., Sec 4182 N. VIKING WAY, SUITE 216, LONG BEACH CA 90808-1475
Joao Dacosta director, officer: COO #810 - 789 WEST PENDER STREET, VANCOUVER A1 V6C 1H2
George Adams director 7535 CONSERVATION ROAD, GUELPH A6 N1H6J1
Terrance George Owen director, officer: CEO 635 FOURTH LINE (UNIT 1), OAKVILLE A6 L6L 5BO
John David Sanderson officer: Chief Medical Officer 9 ISLANDVIEW, IRVINE CA 92604
Yanika S Silina officer: CFO, Treasurer and Secretary 789 WEST PENDER STREET, UNIT 810, VANCOUVER A1 V6C 1H2
Jean M Arnett 10 percent owner 121 - 3989 HENNING DRIVE, BURNABY A1 V5C 6P8
Ean Kremer director, officer: Chief Technology Officer C/O PLANDEL RESOURCES, INC., 4575 DEAN MARTIN DRIVE, STE. 2206, LAS VEGAS NV 89103

Cell MedX (Cell MedX) Headlines

From GuruFocus

Cell MedX Insider Buys 22,500 Shares

By Kyle Ferguson Kyle Ferguson 11-11-2016